1. Emrosi achieved all primary objectives in clinical trial with no safety issues. 2. FDA-approved Emrosi safely manages rosacea symptoms without affecting microbiota. 3. Study published in peer-reviewed Journal supports Emrosi's long-term therapeutic potential. 4. 60 subjects showed no significant changes in microbiome or antibiotic resistance. 5. Rosacea affects millions, highlighting demand for effective treatments like Emrosi.
FAQ
Why Bullish?
Positive clinical trial results and FDA approval indicate strong market potential for Emrosi, similar to past successes of new dermatological treatments boosting companies' stocks.
How important is it?
The article details significant findings about Emrosi that could drive its commercial success, impacting DERM positively.
Why Long Term?
Given Emrosi's FDA approval and established safety profile, the product can achieve prolonged revenue streams, akin to sustained growth observed in similar dermatological products after initial trials.
Journey Medical Corporation Publishes Positive Clinical Trial Results for Emrosi™ (DFD-29)
SCOTTSDALE, Ariz., Dec. 10, 2025 (GLOBE NEWSWIRE) — Journey Medical Corporation (Nasdaq: DERM) announced the publication of encouraging findings from its Phase 1 clinical trial evaluating Emrosi™ (DFD-29) in the Journal of Drugs in Dermatology. This pivotal study focused on the impact of low-dose oral minocycline on the microbial flora of healthy adults, demonstrating no significant safety issues and confirming the treatment’s tolerability over a 16-week period.
Key Findings from the Clinical Trial
The study, identified as DFD-29-CD-006, successfully achieved all three primary objectives. Key outcomes include:
- No significant change in the normal microbiome of the skin, vagina, or gastrointestinal (GI) tract.
- No noticeable development of antibiotic resistance to minocycline.
- No significant emergence of opportunistic organisms compared to the placebo group.
These results bolster the case for Emrosi as a safe therapeutic option for patients suffering from moderate-to-severe rosacea, a condition affecting over 16 million Americans.
Expert Commentary on Emrosi's Role in Dermatology
Claude Maraoui, Co-Founder, President, and CEO of Journey Medical, remarked, “We are very pleased to see these important data published in the Journal of Drugs in Dermatology. This peer-reviewed validation reinforces the differentiated profile of Emrosi as an effective, low-dose oral treatment for rosacea that does not meaningfully disrupt the normal microbiota or contribute to antibiotic resistance." He further emphasized that the current findings highlight Emrosi's potential for long-term use, reflecting the company's commitment to innovative dermatological treatments.
About Emrosi™ and Rosacea
Emrosi® (40 mg Minocycline Hydrochloride Modified-Release Capsules) is FDA-approved for treating inflammatory lesions of rosacea in adults. This chronic skin condition is characterized by symptoms like facial redness, papules, and pustules. According to the National Rosacea Society, rosacea affects approximately 415 million people worldwide, impacting self-confidence and social interactions.
Among those severely affected, 88% report negative impacts on their professional interactions, highlighting the critical need for effective dermatological solutions like Emrosi.
Safety Information and Clinical Evaluation
Emrosi™ has been generally well tolerated, with the most common adverse event reported being dyspepsia. However, it is crucial that patients with hypersensitivity to any tetracyclines avoid the medication. The potential for serious reactions such as anaphylaxis has been documented, necessitating awareness and caution during its use.
Details regarding the DFD-29 Phase 1 clinical trial can be referenced using the identifier NCT05597462.
About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) specializes in the development, marketing, and sale of FDA-approved dermatological prescription medications. Located in Scottsdale, Arizona, the company focuses on providing effective treatment options to address common skin conditions, leveraging an expert team experienced in the dermatology field.
Forward-Looking Statements
This announcement may contain forward-looking statements regarding Journey Medical’s strategies and product development. These statements are inherently uncertain and actual results may differ.